Form 4: Bioxytran Director Acquires Shares in Open Market Transaction

Bioxytran director Dale Conaway acquired 97,535 shares of preferred stock at $0.315 per share on January 6, 2025.

Summary

• On January 6, 2025, Dale Conaway, a director at Bioxytran, Inc., acquired 97,535 shares of preferred stock.
• The purchase price was $0.315 per share.
• Following the transaction, Mr. Conaway directly owns 330,172 shares of preferred stock.

Sentiment

Score: 6

Explanation: The document reflects a routine insider transaction. While the purchase is a positive signal, it's not a major event that would drastically alter sentiment.

Positives

• A director's purchase of shares can be seen as a positive signal of confidence in the company's future prospects.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's stock. It provides transparency into insider trading activity.

Comparison to Industry Standards

• SEC Form 4 filings are a standard practice for all publicly traded companies in the United States.
• The transaction is typical of insider trading activity, where directors and officers buy or sell shares of their company.
• The reporting requirements are consistent across all companies listed on US exchanges.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment due to the director's purchase.

Key Dates

Keywords

Bioxytran, insider trading, share acquisition, preferred stock, director, BIXT